drugset
Drugs / HLX208
last change Feb 2026 re-read 2 minutes ago

HLX208

targets BRAF via inhibition

Developed for
non-small cell lung carcinoma · cancer · colorectal cancer · Erdheim-Chester disease · Langerhans cell histiocytosis · melanoma · primary brain neoplasm · thyroid gland undifferentiated (anaplastic) carcinoma
Investigated by
Shanghai Henlius Biotech

Trials 12 · a red edge is where a trial was stopped

today NCT05902728 · Ph 1 NCT05841940 · Ph 1 NCT05641493 · Ph 1/2 NCT05528406 · Ph 2 NCT05127759 · Ph 2 NCT05114603 · Ph 2 NCT04965220 · Ph 1 NCT05092802 · Ph 2 NCT05102292 · Ph 1/2 NCT05092815 · Ph 2 NCT05065398 · Ph 2 NCT04984369 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT05902728 Jul → Dec 2023 non-small cell lung carcinoma Shanghai Henlius Biotech Completed No outcome recorded
Phase 1 NCT05841940 Jun → Jul 2023 — Shanghai Henlius Biotech Completed No outcome recorded
Phase 1 NCT04965220 Jan 2022 → Jun 2024 cancer Shanghai Henlius Biotech Unknown No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05641493 Feb 2023 → Mar 2025 non-small cell lung carcinoma Shanghai Henlius Biotech Unknown No outcome recorded
Phase 1/2 NCT05102292 Dec 2021 → Jun 2024 thyroid gland undifferentiated (anaplastic) carcinoma Shanghai Henlius Biotech Unknown No outcome recorded
Phase 27 trials
Phase 2 NCT05528406 Oct 2022 → Oct 2024 cancer Shanghai Henlius Biotech Unknown No outcome recorded
Phase 2 NCT05127759 Mar 2022 → Jan 2024 colorectal cancer Shanghai Henlius Biotech Unknown No outcome recorded
Phase 2 NCT05114603 Mar 2022 → Aug 2023 melanoma Shanghai Henlius Biotech Unknown No outcome recorded
Phase 2 NCT05092802 Dec 2021 → May 2023 primary brain neoplasm Shanghai Henlius Biotech Unknown No outcome recorded
Phase 2 NCT05092815 Dec 2021 → Jun 2024 Erdheim-Chester disease, Langerhans cell histiocytosis Shanghai Henlius Biotech Unknown No outcome recorded
Phase 2 NCT05065398 Nov 2021 → Jun 2023 non-small cell lung carcinoma Shanghai Henlius Biotech Unknown No outcome recorded
Phase 2 NCT04984369 Aug 2021 → Jun 2024 — Shanghai Henlius Biotech Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 12 sources stand behind the page.

FieldValueCited text
Known as HLX208 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05102292 ↗
11

NCT05092815 ↗

NCT05092802 ↗

NCT05065398 ↗

NCT04965220 ↗

NCT05902728 ↗

NCT05127759 ↗

NCT05528406 ↗

NCT05114603 ↗

NCT05841940 ↗

NCT04984369 ↗

NCT05641493 ↗
Action Inhibit “BRAF V600E Inhibitor” NCT04965220 ↗
Route Oral “take orally” NCT04965220 ↗
Target BRAF “BRAF V600E Inhibitor” NCT04965220 ↗